Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
暂无分享,去创建一个
V. Chinchilli | L. Demers | A. Lipton | K. Leitzel | H. Harvey | Y. Teramoto | H. Grossberg | K. Konrád | G. Volas | Yoshio A. Teramoto | Kristine Konrad
[1] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[2] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Singleton,et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.
[4] A. Gazdar,et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.
[5] J. Foekens,et al. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. , 1992, Cancer research.
[6] L. Demers,et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[10] R. Akita,et al. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. , 1991, Cancer research.
[11] W. McGuire,et al. Follow-up study of HER-2/neu amplification in primary breast cancer. , 1991, Cancer research.
[12] R. Fourney,et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.
[13] J. Berek,et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. , 1990, Cancer research.
[14] W. Kohr,et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[15] L A Rubin,et al. The soluble interleukin-2 receptor: biology, function, and clinical application. , 1990, Annals of internal medicine.
[16] M. Kraus,et al. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. , 1990, Cancer research.
[17] W. McGuire,et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. , 1990, Cancer research.
[18] T. Akiyama,et al. In vitro and in vivo Release of Soluble erbB‐2 Protein from Human Carcinoma Cells , 1990, Japanese journal of cancer research : Gann.
[19] G. Hortobagyi,et al. c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.
[20] W. McGuire,et al. HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[22] B Angus,et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.
[23] M. Greene,et al. The neu (c-erbB-2) oncogene. , 1989, Seminars in oncology.
[24] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[25] A. Ullrich,et al. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[26] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[27] C R King,et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.
[28] J. Spiess,et al. Production of an epidermal growth factor receptor-related protein. , 1984, Science.
[29] R. Weinberg,et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.
[30] J. Roth,et al. Water-Soluble Insulin Receptors from Human Lymphocytes , 1972, Science.
[31] S. Naber,et al. Detection and quantitation of the human neu oncoprotein , 1991 .
[32] C R King,et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] W. Gullick,et al. c‐erbB‐2 oncoprotein expression in primary human tumors , 1990, Cancer.
[34] M. Cline,et al. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. , 1989, Oncogene.